Pluristem’s stem cell therapy shows promise for Parkinson’s disease
The company is developing PLX cells, which are Pluristem’s placental-derived mesenchymal stem cells that have been expanded in the company’s proprietary PluriX 3-D bioreactor. The in vitro assay
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.